MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD9 Codes        Equipment        Hospitals        Drugs        More..
  
Patient Resources 
Asthma  
Bipolar  
Blood Pressure  
Breast Cancer  
Heart Burn  
Migraine  
  

  


Useful Websites

specialistinfo.com
details of 26,000 UK specialists

Global RPH
medical software

Doctors Lounge
Ask a Doctor and Disease Information

Health News
from Medical News Today.

MRCP 1 Revision
123 Doc medical courses for junior doctors.

CoreyNahman
pharmaceutical news daily

Hospital Search
Worldwide hospital database, search by country or keyword.

DoctorOnline
information for doctors

The Converter Site
metric and imperial conversion tool.
home > drug information > Albenza

Albenza (albendazole)


Company: SmithKline Beecham
Approval Status: Approved June 1996
Treatment for: parasitic infections
Areas: Immunology/Infectious Diseases

| General Information | Clinical Results | Side Effects | Additional Information |


General Information

Other Useful Resources
Albenza has been approved for the treatment of two parasitic infections caused by worms:

  • Hydatid cyst disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus
  • Neurocysticercosis caused by larval forms of the pork tapeworm, Taenia solium

For hydatid disease, the recommended dose for Albenza is 400 mg twice daily with meals for three cycles (each cycle consists of 28 days of dosing followed by a 14-day albendazole-free interval). For neurocysticercosis, the recommended dose is 400 mg twice daily for eight to 30 days.

Albendazole was first marketed outside the United States in 1982 for human use where it is currently marketed under the trade names of Zentel and Eskazole.

< back to top

Clinical Results

Subjects treated with Albenza have shown improvement in more than 80% of the neurocysticercosis subjects and cure or improvement in up to 70%of the hydatid subjects.

< back to top

Side Effects

Side effects were usually mild and resolved without treatment. The most frequently reported side effects by hydatid disease subjects included abnormal liver function, abdominal pain, nausea and vomiting; those reported by neurocysticercosis subjects included headache, nausea, and vomiting.

< back to top

Additional Information

E. granulosus is considered endemic in the Western US sheep-raising areas of Utah, Arizona, and Nevada, but the vast majority of cases occur in new immigrants who have been exposed to the infection years previously in their countries of origin, or in travelers from the United States to endemic areas. Most cysts are found in the liver where, after remaining asymptomatic for decades, they finally produce abdominal pain or a mass. The incidence of hydatid disease in the United States is estimated to be between 100 and 200 new cases diagnosed annually.

T. solium cysticercosis is rare in the United States except in immigrants from endemic areas. It is most common in Latin America, Asia, Russia, and Eastern Europe and is caused by inadequately cooked or raw infected pork. Infection with the adult worm is usually asymptomatic. Severe larval infection, a result of ingestion of contaminated material, may cause muscle pains, weakness, or fever. It can also cause epileptic seizures. The incidence of neurocysticercosis is estimated to be less than 1,000 new cases diagnosed annually.

Worldwide, the prevalence of hydatid disease is estimated to be about one million people mostly found in herding and animal-raising countries and regions of North West China, parts of Northern and Southern Africa, East Africa, Iraq, the Mediterranean basin, Uruguay, Argentina, and Chile. It also occurs occasionally in other countries including the United States, Great Britain, South and East Europe, Australia, and New Zealand. The prevalence of neurocysticercosis is estimated to be about 1.5 million people worldwide. In both diseases, infection with the larva is accidental and transmission from human-to-human does not normally occur.

< back to top



The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.




medilexicon toolbar

download button

Features:

 Medical Dictionary Searches
 ICD9 Searches
 Other Medical Searches
 Search Word Highlighter
 Medical News Articles
 Latest News Headlines

Medical Toolbar

FREE

Download the Medilexicon Medical Search Toolbar on to your internet browser quickly and easily at the touch of a button.

The toolbar will always appear at the top of your internet browser and will allow you to perform many useful features...

>> Click here for more information about the toolbar <<

toolbar



pda medical dictionary
pda software - $15

PDA Medical Dictionary

only $15

Take MediLexicon's abbreviations search with you where-ever you go with our PDA software. As an extra, this software is available with an extra medical dictionary...

>> Click here for more on the PDA Medical Dictionary <<



Privacy Policy   |    Disclaimer      

MediLexicon International Ltd, Mexico Office: + 52 1998 2142733
© 2007 MediLexicon International Ltd. MediLexicon International Ltd